More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.

A recent study published in JAMA Psychiatry has uncovered promising evidence suggesting that glucagon-like peptide-1 (GLP-1) ...

Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

BofA Securities maintained an Underperform rating on shares of Hims & Hers Health, Inc. (NYSE:HIMS) with a steady price ...

These medications were sitagliptin, liraglutide, glimepiride, or insulin glargine U-100. Sitagliptin, liraglutide, and ...

Lexaria Bioscience (LEXX) it has received the necessary independent ethics board approval required for its contract research organization to ...

Ke, X. and Ma, T. (2025) Protective Effect of Liraglutide on Early Renal Fibrosis in Diabetes Mice. Journal of Biosciences and Medicines, 13, 84-91. doi: 10.4236/jbm.2025.131008 .

A recent breakthrough in medical research offers exciting possibilities for people dealing with diabetes and obesity. This ...

The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

The US FDA approved the first generic referencing Victoza, a GLP-1 receptor agonist indicated to improve glycemic control.

The move intensifies an ongoing legal battle, as Novo Nordisk joins its major competitor Eli Lilly in opposing a recent initiative by the Outsourcing Facilities Association to include liraglutide in ...